Compare Crocs, Inc. (CROX) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Danaher Corporation — how do they compare? Crocs, Inc. trades at $114.86 (market cap $5.60B), while Danaher Corporation trades at $219.8 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 27.3× Crocs, Inc.'s market cap, and Danaher Corporation pays a 0.74% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Danaher Corporation for 69 Days on average.
| CROX | DHR | |
|---|---|---|
Market Cap | $5.60B | $152.87B |
Volume | 1,026,773 | 5,228,698 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $242.05 |
52-Week Low | $73.39 | $161.91 |
Typical Hold Time | 96 Days | 69 Days |
Enterprise Value | $7.12B | $175.08B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $114.98, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.55, beating expectations by $0.20, but faces challenges with a negative net income of -$81.20M for 2025. Valuation metrics remain attractive with a P/E of 10.37 and P/S of 1.48, while analyst consensus leans bullish with a $136.78 price target representing 19% upside potential.
CROX presents a mixed investment case with compelling valuation and strong brand positioning offset by recent profitability concerns. The key opportunity lies in the company's product innovation and HEYDUDE brand reset, while risks include consumer spending volatility and execution challenges. With 51% of analysts maintaining buy ratings, the stock offers potential upside if management can restore consistent profitability growth.
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
